Introduction
============

To date, deep brain stimulation (DBS) has already been performed in more than 120,000 patients worldwide and more than 7,000 patients in Japan. These data establish the reliable efficacy and safety of DBS. In particular, DBS has become an important therapeutic strategy for Parkinson's disease (PD).

Following the first use of the stereotactic system for functional neurosurgery by Spiegel and Wycis in 1947, various ablative procedures for PD have been performed. However, these procedures became unpopular after the successful introduction of levodopa. On the other hand, in 1987 Benabid et al.^[@B1],[@B2]^ reported that the high-frequency stimulation of the ventralis intermedius (Vim) nucleus in the thalamus resulted in the complete and reversible cessation of tremors. In the same year, Siegfried et al.^[@B3]^ reported the beneficial effects of the high-frequency stimulation of the globus pallidus interna (GPi). Following these reports, the beneficial effects of the high-frequency stimulation of the subthalamic nucleus (STN) were elucidated by Benabid et al.^[@B4]^ in 1993. This led to a breakthrough in the therapeutic strategy for advanced PD patients, namely DBS.

However, fundamental understanding of the effects of DBS on the pathological neural circuitry remains insufficient. Recent studies have specifically shown the importance of cortico-striato-thalamo-cortical (CSTC) loops, which were identified as functionally and anatomically discrete units.^[@B5]^ The CSTC loops are composed of parallel functionally segregated neural circuits channeling information between the basal ganglia and the cortex via the thalamus.^[@B6],[@B7]^

Three main circuits exist in the CSTC loops, namely, the motor circuit consisting of the sensorimotor and premotor cortices, the associative circuit containing the dorsolateral prefrontal cortex and lateral orbitofrontal cortex, and the limbic circuit consisting of the limbic and paralimbic cortices and medial temporal cortex. From these theoretical backgrounds, it is determined that DBS sometimes affects not only the motor function but also the cognitive and affective functions of PD patients.

Recently, DBS has been used for treating psychiatric diseases and Alzheimer's disease. DBS was already granted a humanitarian device exemption status by the Food and Drug Administration (FDA) for treating obsessive compulsive disorder (OCD) in the United States.^[@B7],[@B8]^ Moreover, DBS has been expected as a therapeutic measure for addiction, eating disorder, post-traumatic stress disorder (PTSD), and minimally conscious state with preliminary successes shown in clinical studies.^[@B9]--[@B13]^

In this article, we review the present state of DBS for PD. In the first part of the review, we describe the appropriate indications and practical effects established in previous studies. The findings of previous studies on the surgical complications and the adverse effects of DBS are also reviewed. In the second part, we discuss the issues that should be resolved including target selection (GPi vs. STN) and the effects of DBS on nonmotor symptoms. In the concluding part, the suitable timing of surgery, symptoms unresponsive to DBS, such as on-period axial symptoms, and the related postoperative programing of stimulation parameters are discussed.

Appropriate Indications of DBS for PD
=====================================

Careful patient selection is a crucial determinant of a favorable functional outcome of DBS. The main targets of DBS for PD are STN and GPi. In addition to these targets, Vim is an effective target for several types of tremor including Parkinson tremor. However, Vim-DBS cannot sufficiently improve akinesia and rigidity, which are the common symptoms of PD. Therefore, Vim-DBS is seldom carried out for the treatment of PD compared with STN-DBS and GPi-DBS.

The basic indication criteria for selecting STN as the target are similar to those for selecting GPi. The clinical features of ideal candidates for both targets have been elucidated in a number of studies. Thus far, levodopa responsiveness has been widely accepted as the best predictive factor for a good outcome of DBS. A majority of medical centers use a levodopa challenge test. In this test, a patient is evaluated as a candidate for DBS when more than 30% improvement in the Unified Parkinson Disease Rating Scale (UPDRS) motor score (part III) is noted after levodopa intake. In addition, patients with severe tremor resistant to medical treatment are also candidates and are expected to show a good outcome. Not only Vim-DBS but also GPi-DBS and STN-DBS are effective for medically resistant Parkinson tremor.

Previously, DBS was usually considered when medical treatment fails. In the case of medical treatment, several side effects, such as wearing-off, dopa-induced dyskinesia (DID), and hallucination, will develop approximately 10 years after the treatment initiation. DBS was often applied to resolve these symptoms related to the medical treatment. However, according to the results of a recent randomized controlled trial (RCT) study,^[@B14]^ the patients who underwent DBS before their medical treatment became ineffective also showed better functional outcome than those treated only medically.

An important point on the difference in the appropriate indications for GPi-DBS and STN-DBS is associated with their efficacy for DID. In general, GPi-DBS has a direct effect on DID. In contrast, STN-DBS can attenuate DID as a result of the reduction in the dose of anti-PD drugs. Incidentally, PD patients with psychiatric symptoms may be considered as candidates for GPi-DBS.

The major contraindications for DBS are serious non-drug-induced preoperative psychiatric symptoms, cognitive dysfunction, and a high overall risk of adverse outcomes of the surgical procedure under general anesthesia for the implantation of an implantable pulse generator (IPG). Care should be taken for PD patients with hypertension and diabetes. Hypertension is a significant risk factor for intraoperative hemorrhage during the DBS electrode implantation, and diabetes is also a significant risk factor for device infection.

Effects of DBS for PD
=====================

The effects of STN-DBS can be simply expressed as the bottom-up effects and substitute effects. The bottom-up effects can improve a patient's activities of daily living (ADL) from the off-period state to the on-period state. The substitute effects of STN-DBS are the effects that take over those of anti-PD drugs in a patient with severe side effects of the drugs. Thus, we can expect that the patient can maintain his/her ADL in the on-period state and reduce his/her levodopa equivalent dose (LED) after STN-DBS surgery.

Regarding the effects of STN-DBS, five large trials,^[@B14]--[@B18]^ controlled vs. best medical treatment, showed a favorable improvement of PD symptoms after STN-DBS. All these trials demonstrated the superiority of STN-DBS over the best medical treatment ([Table 1](#T1){ref-type="table"}). A meta-analysis of 22 studies by Kleiner-Fisman et al.^[@B19]^ showed that the average improvement rate of motor score was 52%.

Long-term results are also available, especially those of three studies showing that the outcomes of STN-DBS in PD patients followed-up for more than 8 years are significant.^[@B20]--[@B22]^ These studies demonstrate the beneficial effects of STN-DBS in the long term ([Table 2](#T2){ref-type="table"}). The motor and ADL scores in the off-state deteriorate after a long-term follow-up but still remain better than the baseline scores.

Similar to STN-DBS, the beneficial effects of GPi-DBS on motor symptoms have been shown by several studies. However, no randomized studies comparing the efficacy of GPi-DBS with that of the best medical treatment have been reported. GPi-DBS has always been compared with STN-DBS.^[@B23]--[@B26]^ Most of the comparison studies showed that the efficacies of these procedures were similar to or that GPi-DBS is less efficacious than STN-DBS ([Table 3](#T3){ref-type="table"}). The rate of LED reduction is markedly different between GPi-DBS and STN-DBS. After GPi-DBS, a marked LED reduction is unexpected. The long-term effects of GPi-DBS on PD patients followed up for 3--6 years have been reported.^[@B27],[@B28]^ From these investigations, the favorable effects of GPi-DBS on tremor and dyskinesia were elucidated. However, the UPDRS scores remained higher than the baseline scores after a long-term follow-up, although speech and gait worsened and LED increased.

Surgical Complications of DBS
=============================

The surgical complications discussed here are comorbidities caused by the surgical procedure for DBS device implantation, which should be differentiated from the adverse effects of DBS, such as psychiatric symptoms and worsening of dyskinesia. We describe the adverse effects of DBS in the next chapter.

The major and serious surgical complications are intracranial hemorrhage, infection, device-related problems, and epileptic seizure. According to a recent meta-analysis of 112 papers,^[@B29]^ the established hemorrhagic complication rate was 4.4% \[95% confidence interval (CI): 3.8--4.9%). However, the occurrence rates of significant permanent neurological deficits due to hemorrhage were relatively low, the average of which was 1.0% (95% CI: 0.6--1.3%). On the other hand, the occurrence rate of infection in DBS patients was 4.0% (95% CI: 3.5--4.5%).^[@B29]^

The device-related problems were the specific complications of DBS, and the main problems were the migration of devices and fracture of leads. Migration occurred in 2.4% of patients (95% CI: 1.9--3.0%) and fracture occurred in 3.0% of patients (95%CI: 2.4--3.6%). Epileptic seizure was noted in 3.2% (95% CI: 2.3--4.0%) of those who underwent DBS. The actual occurrence rate of epileptic seizure was speculated to be much lower than the above-mentioned rate because this meta-analysis did not include analytical reports that did not mention epileptic seizure.^[@B29]^

Many studies showed that a history of hypertension is a significant risk factor for intracranial hemorrhage during DBS surgery.^[@B30]--[@B34]^ The relationship between age and hemorrhage is controversial. From an overall viewpoint, there is no significant increase in hemorrhage rate in elderly patients.^[@B31],[@B35]^

The most common pathogenic bacterium causing infection after DBS is *Staphylococcus aureus,* accounting for 40--60% of all infection cases.^[@B36],[@B37]^ Sillay et al.^[@B38]^ studied the risk factors for infection, namely, patient's age, experience of the surgeon, and the existence of exterior test stimulation period. They found no statistically significant difference in infection rate for these factors they examined. The duration of operation was also studied by some researchers,^[@B39],[@B40]^ but this factor showed no statistically significant relationship with infection.

Adverse Effects of DBS
======================

The adverse effects of DBS such as cognitive decline and psychiatric symptoms are complex and a nonbiased incidence of such effects is not easy to determine, because these are also associated with the duration of PD and the reduction in the dose of anti-PD drugs. The disturbance of verbal fluency is the only significant adverse effect of DBS that almost all researchers found.

The common adverse effects that sometimes appear immediately after the surgery for DBS, especially in STN, are restlessness, hallucination, and cognitive decline. However, these symptoms frequently do not persist for a long time and do not disturb the patient's quality-of-life (QOL).

After a long-term follow-up, dysarthria and apathy were sometimes noted. Dysarthria worsens in association with increase in stimulation intensity spreading in the corticospinal tract. Apathy seems to be related to the reduction in the dose of anti-PD drugs especially in the case of rapid reduction in the dose of levodopa. Cognitive decline is also present in the chronic state, which degrades the QOL of PD patients and is a serious problem for the families of PD patients.

Regarding cognitive function after DBS for PD, according to the results of meta-analysis by Appleby et al.,^[@B41]^ severe and persistent cognitive decline seldom occurs after the intervention. However, a number of studies consistently showed the disturbance of verbal fluency after STN-DBS. A recent controlled randomized study with a 3-year follow-up has also shown that the occurrence rate of the disturbance of verbal fluency was significantly higher in patients with STN-DBS.^[@B42]^ Other than the decline of phonological and semantic verbal fluency, an impaired response inhibition in conflict situation as assessed by the Stoop test^[@B43]^ or go/no-go tasks^[@B44]^ is regarded as another symptom suitable to disturb after DBS. According to the results of the meta-analysis of cognitive function after DBS by Parsons et al.,^[@B45]^ it is rare that severe and long-term persistent cognitive decline occurs after STN-DBS and that the patient's QOL deteriorates persistently. On the other hand, it was reported that the withdrawal of levodopa therapy is related to cognitive decline.^[@B46]^

It has been considered that the effect of DBS on cognitive function is smaller in GPi than in STN. In particular, the disturbance of verbal fluency, which sometimes occurs after STN-DBS, seldom occurs after GPi-DBS. Meta-analysis by Videnovic et al.^[@B47]^ revealed that the occurrence rates of cognitive decline and behavioral abnormalities were significantly lower in GPi-DBS than in STN-DBS.

In addition to cognitive decline, psychiatric symptoms should also be considered as important adverse effects of STN-DBS. However, care should be taken for patients with dementia with Lewy bodies (DLB) because this condition complicates PD and also causes cognitive decline and psychiatric symptoms.

DBS induces psychiatric symptoms such as hallucination, mood change, ICD, and dopamine dysregulation syndrome (DDS). These symptoms usually occur after STN-DBS. It does not necessarily mean that there are no symptoms at all after GPi-DBS, but they are very rare compared with those occurring after STN-DBS.

Regarding the psychiatric symptoms that appear immediately after the surgery for STN-DBS, they are highly expected to disappear completely even when severe hallucination is present. However, hallucination present before the surgery often worsens after the surgery. In such cases, preoperative identification of the cause of hallucination is important. In particular, it is important to differentiate between drug-induced hallucination and hallucination as a complication of dementia with Parkinson disease (PDD) and/or DLB. Drug-induced hallucination is expected to improve after STN-DBS because of the reduction in LED. However, a patient with hallucination as a complication of the disease itself should be excluded as a candidate for STN-DBS at the beginning of the evaluation stage for operative indication.

Depression and mania may occur after STN-DBS. Basically, we speculate that the combined effects of anti-PD drugs and STN-DBS on the limbic circuit cause such mood change. Therefore, a balance between the reduction in the dose of levodopa and the increase in STN-DBS intensity would be important. In addition to this balance, the STN part stimulated would be important. Ventromedial STN links the limbic circuit of the CSTC loops and is closely associated with emotion and mood.

The same theoretical background would be applied to impulsive compulsive disorder (ICD) and DDS. It is conceivable that ICD is one of the phenotypes of the hyperactive state of the limbic circuit of the CSTC loops. Moreover, DDS is exactly the disproportionate state of the CSTC loops. Caution is necessary when ICD and DDS occur after STN-DBS because they sometimes upset the proportionate balance of the CSTC loops. It was reported that the occurrence rate of ICD was significantly higher in the group with STN-DBS than in the medication-only group.^[@B48]^

Therefore, caution should be exercised regarding the balance between the dose of anti-PD drugs and DBS intensity in patients with psychiatric symptoms. Excessive reduction in the dose of levodopa and/or agonists with insufficient DBS intensity may induce depressive mood or apathy. In contrast, excessive accumulation of dopaminergic drugs and marked DBS of the limbic circuit of the CSTC loops would induce hyperactive-state symptoms such as mania, aggressiveness, and ICD. These strongly suggest that the balance between LED and DBS intensity is important.

Selection of Target
===================

Selection of the best DBS target for PD is a recent topic of discussion in this field. To date, three targets have been identified for PD treatment in general: Vim, GPi, and STN. Of these targets, selection of Vim as the target for DBS does not improve any of the symptoms of PD except for tremor. Vim is, therefore, selected for only a few patients with limited clinical conditions, namely, old age and predominant longstanding tremor.

There is no general consensus on which is the best target, GPi or STN for PD. Before the conduct of detailed RCTs, there was some impression that STN is slightly superior to GPi. However, a recent 5-year follow-up study^[@B28]^ has revealed that there is no significant difference between GPi and STN in their effects on the motor symptoms. The meta-analysis of studies comparing these two targets^[@B49]^ indicated the significant superiority of GPi for patients with postural instability and gait disturbance.

There are some noteworthy RCTs comparing GPi with STN.^[@B26],[@B50],[@B51]^ The CSP468 Study Group^[@B26]^ indicated no significant difference in motor improvement between these two targets, and the incidence of adverse effects, especially cognitive decline, was significantly low for GPi as the target. Another RCT^[@B51]^ showed significant improvement of PD symptoms for STN as the target, and the incidence of adverse effects was almost the same for both targets.

As mentioned above, it is still difficult and probably impossible to determine which is the best target in general. Different aspects need to be considered. We should consider which is the suitable target for each patient because each target has different features. Probably, GPi is better than STN as a target in terms of improving gait, speech, postural instability, and dyskinesia. On the other hand, the prominent STN-DBS effect is reduction in LED, which leads to the improvement of the adverse events induced by anti-PD drugs, such as ICD, hallucination, and aggressiveness.

Regarding the characteristics of patients that should be considered when selecting the target, age may be important because the reduction in LED would largely benefit young patients who will cope with the disease over a long period. On the other hand, dyskinesia is sometimes the most intolerable symptom for elderly patients and it is easily affected by psychiatric adverse events induced by a change in the dose of anti-PD drugs. In addition, the battery lifetime is usually shorter for GPi-DBS because much more energy is needed to stimulate the large anatomical structure of GPi.

Effects on Nonmotor Symptoms
============================

There are several types of nonmotor symptom induced by DBS. The symptoms we should pay attention to are autonomic symptoms, poor sleep quality, and pain.

PD patients often have autonomic symptoms such as orthostatic hypotension, constipation, neurogenic bladder, dyshidrosis, and sexual dysfunction. However, the effects of DBS on autonomic symptoms have not been studied in detail and remain obscure. Changes in blood pressure and heart rate after STN-DBS have been reported.^[@B52]^ Holmberg et al.^[@B53]^ conducted a prospective study and found that there was no significant difference in circulatory autonomic function between the patients with STN-DBS and those treated only with anti-PD drugs. Erola et al.^[@B54]^ compared circulatory autonomic function before STN-DBS with that after 1 year of STN-DBS, and they found no statistically significant difference.

Constipation is a common autonomic symptom in PD patients. It is often recognized from the onset of the disease. The improvement of constipation after STN-DBS is often noted. However, improvement is only partial and usually patients need to take laxative drugs even after STN-DBS. The improvement of constipation appears to be related to the improvement of motor functions. Bladder dysfunction is also frequently noted in PD patients. There are some reports mentioning the direct effect of STN-DBS on bladder dysfunction. However, such an effect remains to be confirmed.

The efficacy of STN-DBS in improving sleep has been studied by sleep poligraphy. It was reported that the durations of both the slow-wave sleep and rapid eye movement (REM) sleep were extended after STN-DBS and the degree of extension was associated with the degree of improvement of motor functions.^[@B55]^ A study with a two-year follow-up also showed a significant increase in total sleeping time, and this increase was associated with the improvement of bradykinesia. The reduction in LED results in a decrease in the time of sleep during the daytime and an improvement of the quality of sleep at nighttime.

A majority of PD patients have experienced chronic pain. A cohort study by Broetz et al.^[@B56]^ showed that 74% of 101 patients had back pain. Usually, PD-related pains are classified as (1) musculoskeletal pain, (2) dystonic pain, (3) somatic pain, (4) radicular/peripheral pain, and (5) central pain. The presence of pain exacerbation during the off-period is important for differentiating PD-related pain from other types of pain.

PD-related pain is mainly associated with a chronic enhancement of muscle contraction, which is marked in musculoskeletal pain and dystonic pain. Practically, the improvement of musculoskeletal pain correlates with the improvement of rigidity, and the improvement of dystonic pain correlates with the improvement of dystonia after STN-DBS.

Pain threshold is also significantly associated with blood levodopa concentration. A decrease in blood levodopa concentration leads to the decrease in pain threshold.^[@B57]^ Therefore, patients sometimes complain of severe body discomfort after the withdrawal of levodopa. It was reported that the blood levodopa concentration in PD patients with pain is significantly lower than those in PD patients without pain and in normal subjects.^[@B58]^

In general, clinical research revealed the beneficial effects of STN-DBS on PD-related pain. Kim et al.^[@B59]^ reported that 20 of the 23 patients (87%) showed improved PD-related pain after STN-DBS. In particular, dystonic pain and central pain improved markedly. However, Oshima et al.^[@B60]^ reported that central pain poorly responded to STN-DBS and dystonic pain and musculoskeletal pain markedly improved after 1 year of STN-DBS.

Other Issues and Resolution
===========================

There are other issues regarding DBS for PD that need to be resolved. Postural instability and gait disturbance are the most disabling symptoms of PD. Several studies have shown that such symptoms present in the off-period are improved by STN-DBS, but those present in the on-period are not improved by this stimulation.^[@B61]--[@B63]^ Meta-regression analysis by St George et al.^[@B49]^ has indicated that GPi-DBS may have a better effect on gait disturbance than STN-DBS at least on the basis of their 2-year data.

Dopa-unresponsive postural instability and gait disturbance are important problems to consider from the viewpoints of selecting the appropriate stimulation target and programing of stimulation parameters. The pedunculopontine nucleus (PPN) is a new target for gait disturbance.^[@B64]^ However, there is a wide variability of the results of studies of PPN as a target^[@B65],[@B66]^; therefore, further studies are required.

To enhance the benefits of DBS, some investigators examined the timing of intervention of DBS. In particular, a recent prospective study by Schuepbach et al.^[@B14]^ is worth mentioning. Previously, DBS as a therapeutic strategy for PD was considered as a last resort when medical treatment fails. Schuepbach et al.^[@B14]^ have disproved such a thought on the basis of the results of their study. They randomly assigned 251 PD patients with early motor complications (mean disease duration, 7.5 years) to undergo STN-DBS plus medical therapy or medical therapy alone and compared the functional outcomes using The Parkinson's Disease Questionnaire (PDQ)-39. Their results suggest the superiority of STN-DBS plus medical therapy even at an early stage of PD. Likewise, age at surgery and PD onset age of patients would be important factors affecting the efficacy of STN-DBS for PD.^[@B67]^

Further enhancement of STN-DBS benefits would be realized by accumulating new knowledge on the programing of stimulation parameters. The motor component is known to exist in the dorsolateral part of STN. The main part for stimulation, either in the monopolar stimulation or bipolar stimulation, is consistently placed in this part. However, the stimulation site placed within the area above the STN appears to have beneficial effects on hyperkinetic symptoms such as dyskinesia and tremor.^[@B68]^ On the other hand, nigral stimulation for resistant axial motor impairment, which generally shows limited response to dopaminergic medication and STN-DBS, was reported.^[@B69]^ A RCT disclosed the statistically significant improvement of freezing of gait and the possible usefulness of the combined stimulation of STN and the substantia nigra pars raticulata for the PD patients with levodopa-unresponsive axial motor symptoms. In addition, Moreau et al.^[@B70]^ reported a new strategy of STN-DBS against freezing of gait. Their results prompt the consideration of two-stage STN-DBS frequency optimization, with stimulation at 130 Hz and the usual voltage during the initial years and then at 60 Hz at a higher voltage in PD patients who develop severe gait disturbance.
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###### 

Large controlled trials: deep brain stimulation vs. medical treatment

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors                     Year of publication   Target no. of pts.   Follow-up period   Improvement                           Adverse events
  --------------------------- --------------------- -------------------- ------------------ ------------------------------------- ------------------------------------------------------------------
  Deuschl et al.^[@B15]^      2006                  STN-DBS 78\          6 months           DBS, better\                          Serious: DBS, worse (p \< 0.04)\
                                                    Medical 78                              PDQ-39 (p = 0.02)\                    DBS 13%\
                                                                                            UPDRS-III(p \< 0.001)                 Medical 4%\
                                                                                                                                  Frequency: Medical, worse (p = 0.08)\
                                                                                                                                  DBS 50%\
                                                                                                                                  Medical 64%

  Weaver et al.^[@B16]^       2009                  STN 60\              6 months           DBS, better\                          DBS, worse (p \< 0.001) 1 death secondary to hemorrhage
                                                    GPi 61\                                 Motor function (p \< 0.001)\          
                                                    Medical 134                             Quality-of-life scores (p \< 0.001)   

  Williams et al.^[@B17]^     2010                  STN-DBS 174\         1 year             DBS, better\                          Serious adverse events: DBS, worse 20 pts. in DBS (1 death)\
                                                    GPi-DBS 4\                              PDQ-39 (p = 0.001)                    13 pts. in medical
                                                    Medical 183                                                                   

  Okun et al.^[@B18]^         2012                  STN on group 101\    1 year             DBS on group, better\                 DBS infection 4% and intracranial hemorrhage 3%
                                                    STN off group 35                        Good quality on time (p = 0.003)      

  Schuepbach et al.^[@B14]^   2013                  STN-DBS 124\         2 years            DBS, better\                          Serious adverse events: DBS, worse 54.8% of DBS 44.1% of medical
                                                    Medical 127                             PDQ-39 (p = 0.0021)                   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

GPi: globus pallidus interna, PDQ: Parkinson's Disease Questionnaire, pts.: patients, STN-DBS: subthalamic nucleus-deep brain stimulation, UPDRS: Unified Parkinson Disease Rating Scale.

###### 

Long-term results of subthalamic nucleus-deep brain stimulation followed up for more than 8 years

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors                    Year of publication   No. of pts.   Follow-up period   Motor improvement compared with baseline                LED reduction           Significant issues
  -------------------------- --------------------- ------------- ------------------ ------------------------------------------------------- ----------------------- -----------------------------------------
  Fasano et al.^[@B20]^      2010                  20            8 years            UPDRS motor score: Better than base line (p \< 0.001)   60.3% reduced           Gait and postural instability\
                                                                                                                                                                    Executive function

  Castrioto et al.^[@B21]^   2011                  18            10 years           UPDRS motor score better than baseline (p = 0.007)      Significantly reduced   Axial signs showed progressively worsen

  Zibetti et al.^[@B22]^     2011                  14            9 years            UPDRS motor score: 42% improved\                        39% reduced             Cognitive decline
                                                                                    ADL score: no improvement\                                                      
                                                                                    Motor complication: 59% improved                                                
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ADL: activities of daily living, LED: levodopa equivalent dose, pts.: patients, UPDRS: Unified Parkinson Disease Rating Scale.

###### 

Comparison study related to globus pallidus interna and subthalamic nucleus

  -----------------------------------------------------------------------------------------------------------
  Authors                    Year of publication   No. of pts.   Follow-up period   Efficacy     Safety
  -------------------------- --------------------- ------------- ------------------ ------------ ------------
  DBS for PD Study Group     2001                  STN 96\       6 months           STN \> GPi   --
                                                   GPi 38                                        

  Anderson et al.^[@B24]^    2005                  STN 10\       1 year             STN \> GPi   GPi \> STN
                                                   GPi 10                                        

  Okun et al.^[@B25]^        2009                  STN 22\       7 months           STN = GPi    GPi \> STN
                                                   GPi 23                                        

  Follett et al.^[@B26]^     2010                  STN 147\      2 years            STN = GPi    GPi \> STN
                                                   GPi 152                                       

  St George et al.^[@B49]^   2010                  STN 261\      4 years            GPi \> STN   --
                                                   GPi 40                                        

  Weaver et al.^[@B50]^      2012                  STN 70\       3 years            STN = GPi    STN \> GPi
                                                   GPi 89                                        

  Odekerken et al.^[@B51]^   2013                  STN 63\       1 year             STN \> GPi   STN = GPi
                                                   GPi 65                                        
  -----------------------------------------------------------------------------------------------------------

GPi: globus pallidus interna, PD: Parkinson's disease, pts.: patients, STN: subthalamic nucleus.
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